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Endocannabinoids and cannabinoid CB1 receptors are known to play a generalized role in energy homeo-
stasis. However, clinical trials with the first generation of CB1 blockers, now discontinued due to psychiatric
side effects, were originally designed to reduce food intake and body weight rather than the metabolic risk
factors associated with obesity. In this review, we discuss how, in addition to promoting energy intake,
endocannabinoids control lipid and glucose metabolism in several peripheral organs, particularly the liver
and adipose tissue. Direct actions in skeletal muscle and pancreas are also emerging. This knowledge
may help in the design of future therapies for the metabolic syndrome.An ‘‘Expanded’’ View of the Endocannabinoid System
In the nearly 50 years since the identification of the principal
active component of Cannabis sativa, the cannabinoid D9-tetra-
hydrocannabinol (D9-THC) (Gaoni and Mechoulam, 1964), great
strides have been made in identifying and understanding the
endogenous mediators, i.e., the endocannanabinoids, that this
natural product biologically mimics. The most-studied endocan-
nabinoids,N-arachidonoylethanolamide (anandamide; AEA) and
2-arachidonoylglycerol (2-AG), members of the fatty acid amide
(FAA) and monoacylglycerol (MAG) families of neutral lipids,
respectively, are produced, often with their congeners, from
cell membrane phospholipids after cell stimulation and are
immediately released to target the same cannabinoid receptors
(CB1 and CB2) as D9-THC (Di Marzo, 2008b). The endocannabi-
noid system (ECS) as a whole refers to endocannabinoids and
the proteins that regulate their production and degradation, as
well as to the receptors through which they signal.
ECS ‘‘tone’’ within a biological system is mostly the result of
the regulation of endocannabinoid levels as modulated by
different, often concurring, enzymatic cascades, which are
nearly ubiquitously expressed. Several pathways have been
proposed to mediate AEA formation, such as, for example, the
hydrolysis of N-acylphosphatidylethanolamine (NAPE) by
NAPE-selective phospholipase D or the combinatorial action of
a,b-hydrolase domain-containing 4 and glycerophosphodiester-
ase 1 on NAPE precursors (Muccioli, 2010). The production of 2-
AG results from the sequential hydrolysis of sn-2-arachidonic
acid (AA)-containing diacylglycerol (DAG) membrane phospho-
lipids by phospholipase C (PLC) and diacylglycerol lipase
a (DAGLa) or b (DAGLb) (Muccioli, 2010). Degradation of AEA
and 2-AG proceeds through their hydrolysis primarily by fatty
acid amide hydrolase (FAAH) and monoacylglycerol lipase
(MAGL), respectively, resulting in the release of ethanolamine
or glycerol, respectively, along with AA (Muccioli, 2010), which,
when produced from 2-AG in the brain, may act as a precursor
of prostanoids (Nomura et al., 2011). Alternatively, both AEA
and 2-AG are subject to oxidative metabolism mediated
by prostaglandin-endoperoxide synthase 2/cyclooxygenase 2
(PTGS2/COX-2) resulting in the eventual formation of variousbiologically active prostaglandin-ethanolamides and prosta-
glandin-glycerol esters, respectively (Kozak et al., 2004).
The canonical receptors for AEA and 2-AG are the mostly Gi/o-
protein-coupled CB1 and CB2 receptors. Their activation by
AEA and 2-AG results in a host of biochemical responses that
are often cell-type specific, including the inhibition of various
voltage-gated Ca2+ channels and adenylate cyclase activity re-
sulting in lower cAMP levels and the activation of K+ channels,
phospholipases, and mitogen-activated protein kinase (MAPK)
pathways. CB1 is highly expressed throughout the central
nervous system in neurons that regulate feeding, energy expen-
diture, and reward, as well as in peripheral organs that are critical
for metabolic homeostasis. While there is some evidence that
CB2 is also expressed neuronally, this receptor is mainly found
within cells of the immune system, in line with its role as a major
modulator of immune function (Howlett, 1995; Pertwee and
Ross, 2002).
AEA and 2-AG also target noncannabinoid receptors. AEA
activation of the transient receptor potential vanilloid 1 (TRPV1)
channel, responsible for the sensation of heat produced by
spicy peppers, increases intracellular Ca2+ levels and produces
several biological effects that sometimes oppose those pro-
duced by CB1 and CB2 activation (Di Marzo and De Petrocellis,
2010). At higher concentrations, AEA is also able to act within
the nucleus by binding to the peroxisome proliferator-activated
receptorg (PPARg) and activating transcription (Bouaboula
et al., 2005; Gasperi et al., 2007; Karaliota et al., 2009), although
there is still little evidence for such mechanism to occur in vivo.
Our understanding of yet other ‘‘endocannabinoid receptors’’
proposed so far is limited, and in some cases controversial,
requiring further investigation. On the other hand, it is now clear
that AEA and 2-AG congeners, i.e., several FAAs and MAGs,
respectively, are biosynthesized and/or degraded by the same
enzymes as the two endocannabinoids but interact with non-
CB1, non-CB2 receptors. The best established examples are
N-oleoylethanolamine (OEA) and N-palmitoylethanolamine
(PEA), which activate both PPARa and TRPV1, and 2-oleoylgly-
cerol, a potent agonist at the orphan receptor GPR119, the
activation of which in the small intestine stimulates the releaseCell Metabolism 17, April 2, 2013 ª2013 Elsevier Inc. 475
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Hansen et al., 2012). The ‘‘promiscuity’’ of endocannabinoids,
the ‘‘redundancy’’ of their metabolic pathways, and their being
produced or degraded together with, or their giving rise to,
other bioactive lipid mediators expands and complicates the
interpretation of their role in metabolic control, posing new
exciting challenges and opportunities for the development of
endocannabinoid-based therapies against metabolic disorders.
Control of Metabolism by the Central/Neuronal
Endocannabinoid System and Its Dependence on the
Nutritional Status andCaloric andHedonic Value of Food
Within the central nervous system, endocannabinoids function,
in general, in a retrograde manner, being produced by postsyn-
aptic cells and acting on CB1 in presynaptic terminals to inhibit
excitatory or inhibitory neurotransmitter release (Ohno-Shosaku
et al., 2012). Endocannabinoid release occurs immediately
after biosynthesis from postsynaptic phospholipids, with no
intermediate storage in vesicles like for other neuromodulators.
Thus, endocannabinoids are ideal mediators for responding in
real-time to the ever-changing feeding state of an organism.
They regulate appetite and food intake in a local manner by
modulating, via activation of CB1 receptors, the activity of hypo-
thalamic neurons and, subsequently, the release of orexigenic
and anorexigenic neuropeptides, as well as the function of
mesolimbic and brainstem neurons, by translating input infor-
mation from the periphery to these neurons, thereby partici-
pating in both the homeostatic (i.e., based on energy balance)
and hedonic (i.e., based on the incentive value of food) aspects
of food intake (Broberger, 2005; Di Marzo et al., 2009b).
It is now well accepted that CB1 activation by D9-THC or
synthetic CB1 agonists stimulates feeding. Injection of AEA or
2-AG in the hypothalamus and nucleus accumbens elicits
increased feeding also in satiated rodents via CB1 activation
(Jamshidi and Taylor, 2001; Kirkham et al., 2002). On the other
hand, endocannabinoid levels increase significantly within the
hypothalamus and accumbens in response to fasting, returning
to normal after refeeding, without changing in brain areas not
involved in feeding (Kirkham et al., 2002). This regulation is medi-
ated, at least in part, through the action of feeding-regulated
hormones, in particular, anorexigenic leptin and orexigenic
ghrelin or glucocorticoids, which decrease and increase endo-
cannabinoid levels within the hypothalamus, respectively, and
become deregulated during obesity, thus resulting in elevated
hypothalamic endocannabinoid tone (Di Marzo et al., 2001;
Malcher-Lopes et al., 2006; Kola et al., 2008). Activation of the
ECS also affects the reward and reinforcement circuits in the
mesolimbic system, especially the nucleus accumbens and
ventral tegmental area, where the ECS is highly expressed and
interacts with both dopaminergic and opioidergic pathways,
resulting in a preference for highly palatable food (Melis et al.,
2007; Verty et al., 2004). For example, D9-THC increases
sucrose-induced hedonic activity and dopamine release into
the nucleus accumbens (De Luca et al., 2012), whereas CB1
antagonism reduces the increase of extracellular dopamine
release induced in this nucleus by a novel highly palatable food
(Melis et al., 2007). Furthermore, CB1 and m-opioid blockade
synergize at reducing food intake and body weight in rodents
(Lockie et al., 2011; Tallett et al., 2009) (Figure 1).476 Cell Metabolism 17, April 2, 2013 ª2013 Elsevier Inc.Indeed, both pharmacological and genetic inhibition of CB1
results in hypophagia (Colombo et al., 1998; Di Marzo et al.,
2001). In a recent study, virally mediated knockdown of CB1
within the mouse hypothalamus by 60% had no effects on basal
food consumption, although the animals were less responsive to
the hypophagic activity of the CB1 inverse agonist rimonabant,
and insensitive to the anorexigenic actions of leptin, suggesting
that this hormone relies entirely on its inhibition of CB1 tone to
produce its effects in this brain area (Cardinal et al., 2012). Impor-
tantly, the orexigenic effect of ghrelin is also lost in rodents in
which CB1 receptors are pharmacologically or genetically inac-
tivated (Kola et al., 2008). It is not known, however, whether the
effects of leptin and ghrelin on the hedonic neural correlates of
food intake at the level of the mesolimbic nuclei are also exerted
via modulation of ECS signaling. Interestingly, in healthy volun-
teers, consumption of favorite food, as compared to normal
food, is accompanied by elevated plasma 2-AG levels which
correlate positively with plasma ghrelin levels (Monteleone
et al., 2012). It is not known whether this phenomenon reflects
a direct or indirect stimulatory action by palatable-food-
enhanced ghrelin signaling on endocannabinoid levels in the
brain or peripheral tissues or, rather, the change in small intestine
endocannabinoid levels after mouth exposure to fat, as shown in
a recent study in rats (DiPatrizio et al., 2011). The latter seems
less likely, considering that elevation of plasma 2-AG levels
was observed also in anticipation of the favorite food, and not
only after its consumption.
Perhaps surprisingly, CB1 activation can also produce hypo-
phagic actions, depending on the type of axon terminals, i.e.,
excitatory versus inhibitory, where it occurs. In an elegant
study using selective CB1 deletion in either glutamatergic
or GABAergic forebrain neurons, exogenous D9-THC, as well
as endocannabinoid level elevation induced by fasting or expo-
sure to palatable food, produced hyperphagic or hypophagic
effects depending on the restriction of their action to CB1 on glu-
tamatergic or GABAergic terminals, respectively (Bellocchio
et al., 2010). In the lateral hypothalamus, however, CB1 activa-
tion results in retrograde inhibition of GABA or glutamate release
from inputs onto melanin-concentrating hormone (MCH) or
orexin-1 releasing neurons, thereby resulting in disinhibition or
inhibition of stimulation, respectively, of two orexigenic signals
and, potentially, in orexigenic or anorexic effects (Figure 1). On
the other hand, presynaptic CB1 activation also inhibits gluta-
mate release to parvocellular neurons, resulting in the inhibition
of the release into the paraventricular nucleus of the anorectic
corticotropin-releasing hormone (CRH) (Jo et al., 2005; Kola
et al., 2008; Malcher-Lopes et al., 2006). Since global and condi-
tional glutamatergic CB1/ mice exhibit the same hypophagic
phenotype after fasting or exposure to palatable foods (Belloc-
chio et al., 2010), one must surmise that the effect of CB1 inhibi-
tion of glutamatergic signaling overall predominates over that of
GABAergic signaling when one needs to explain the hyperphagic
effects of D9-THC and the hypophagic effects of CB1 inverse
agonists in wild-type mice. However, it should be remembered
that the hypothalamus can be rapidly ‘‘rewired,’’ in terms of
what and how many neurons are regulated by excitatory versus
inhibitory inputs, in fasted versus ad-lib-fed or in lean versus
obese animals, often as a consequence of changes in leptin or
glucocorticoid signaling (Crosby et al., 2011; Pinto et al., 2004).
Figure 1. Endocannabinoid- and CB1-Mediated Control of Central Functions Affecting Food Intake and Metabolism
2-AG, 2-arachidonoylglycerol; BAT, brown adipose tissue; CRH, corticotrophin-releasing hormone; EC, endocannabinoid; glut., glutamate; MCH, melanin-
concentrating hormone.
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tin-deficient or leptin-resistant obese mice, CB1-expressing
presynaptic inputs change from predominantly excitatory to
inhibitory, resulting in elevated retrograde disinhibition, rather
than inhibition of activation, and increased orexin-A release in
target areas, which might contribute to hyperphagia in obesity
(L. Cristino and V.D., unpublished data) (Figure 1).
Under conditions of diet-induced obesity (DIO) in mice, endo-
cannabinoid levels are upregulated within the hippocampus,
which is an important substrate of hedonic eating, indicating
that highly palatable foods might be more satisfying under
these conditions, resulting in a vicious circle leading to obesity(Massa et al., 2010). Also in the hypothalamus, 2-AG is tran-
siently or permanently upregulated after acute or prolonged
consumption, respectively, of a high-fat diet (HFD) and seems
to determine, via CB1 receptors, the preference for such diet
over a normal chow (Bisogno et al., 2012; Higuchi et al., 2011).
Hypothalamic 2-AG level elevation, which accompanies
impaired leptin signaling (Di Marzo et al., 2001), might also
participate in peripheral metabolic dysfunctions, such as excess
white adipose tissue (WAT) accumulation and hepatic glucose
production, by causing insulin resistance in the mediobasal
hypothalamus, as suggested by studies in rats either treated
with intracerebroventricular infusion of a CB1 agonist or givenCell Metabolism 17, April 2, 2013 ª2013 Elsevier Inc. 477
Figure 2. Endocannabinoid Function in the Adipose Tissue
AEA, anandamide; BAT, brown adipose tissue; EC, endocannabinoid; FA, fatty acid; FAS, fatty acid synthase; LPL, lipoprotein lipase; PPARg, peroxisome
proliferator-activated receptor-g; TG, triglyceride.
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Accordingly, selective deletion of CB1 receptors in central
neurons confers resistance to HFD-induced obesity (Pang
et al., 2011), whereas CB1 deletion in both central and sympa-
thetic neurons results in increased thermogenesis (Quarta
et al., 2010). These data emphasize the key role of central-
neuronal CB1 receptors in the control of both central and
peripheral energy homeostasis. However, since central mecha-
nisms of metabolic control can be both up- and downstream
to peripheral ones, these findings in conditional CB1 knockout
mice do not rule out a role for peripheral, nonneuronal CB1
receptors in the metabolic syndrome (Figure 1).
Control of Metabolism by the Peripheral
and Nonneuronal Endocannabinoid System:
Well-Established Mechanisms
White and Brown Adipocyte Endocannabinoids:
Lipolysis, Lipogenesis, Inflammation,
and Thermogenesis
The WAT is the main energy repository organ of the human body
through its capability of accumulating triglycerides. The WAT
must be able to respond to the energetic status of the organism478 Cell Metabolism 17, April 2, 2013 ª2013 Elsevier Inc.relatively quickly, by expanding in size not only through the accu-
mulation of lipid stores but also via the recruitment of new adipo-
cytes or by mobilizing lipid stores through increased metabolic
flexibility (i.e., enhanced mitochondrial function and biogenesis)
(Ahmadian et al., 2010). This ability results in the marked differ-
ences observed in the amount of WAT between individuals,
which is not observed for other organ systems. In addition, the
WAT is an endocrine organ that releases adipokines, like leptin
and adiponectin, which are per se able to modulate energy
homeostasis.
The presence of CB1 in mature white adipocytes, but not in
preadipocytes, was demonstrated in both human primary cells
and rodent primary cells and cell lines (Cota et al., 2003; Bensaid
et al., 2003; Roche et al., 2006). These cells also express
enzymes for the production and degradation of endocannabi-
noids (Blu¨her et al., 2006; Matias et al., 2006). Several studies
have highlighted the function of CB1 receptors for 2-AG and
AEA in the regulation of adipogenesis and lipogenesis. The bio-
logical actions reported thus far for CB1 activation in white
adipocytes in vitro are all in the direction of maximizing fatty
acid (FA) de novo biosynthesis and triglyceride (TG) accumula-
tion andminimizing lipolysis (Figure 2). They include (1) activation
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lipase (necessary for de novo FA biosynthesis and TG accumu-
lation, respectively); (2) inhibition of cAMP release, adenosine
monophosphate-activated protein kinase (AMPK), and mito-
chondrial biogenesis (and, as a consequence, of lipolysis and
FA oxidation); (3) stimulation of PPARg expression and adipo-
genesis; and (4) inhibition of adiponectin production in hyper-
trophic adipocytes (Di Marzo, 2008a; Silvestri et al., 2011;
Vettor and Pagano, 2009). Opposite effects are, instead, usually
observed after treatment of cultured adipocytes with CB1
receptor inverse agonists, which also reduce proinflammatory
markers (Ge et al., 2012) in endocannabinoid-overproducing
hypertrophic adipocytes. In fact, there is evidence that endocan-
nabinoid production in white adipocytes is under the negative
control of insulin (via stimulation of Faah expression) (D’Eon
et al., 2008), PPARg, and leptin (Matias et al., 2006), whereas
CB1 expression is downregulated by PPARd, after exercise in
rats (Yan et al., 2007), and by PPARg (Pagano et al., 2007).
Importantly, leptin also inhibits WAT endocannabinoid levels
through its action in the mediobasal hypothalamus (Buettner
et al., 2008). These mechanisms may act as negative feedback
to control endocannabinoid tone but become deranged after
conditions leading to obesity, such as prolonged HFD and lack
of exercise, thus subsequently contributing to further fat accu-
mulation and macrophage infiltration in the WAT via excess
CB1 activity. On the other hand, endocannabinoid/CB1 tone
stimulates leptin signaling, since blockade of CB1 receptors
with JD5037, a peripherally restricted CB1 inverse agonist,
reverses hyperleptinemia in DIO mice by decreasing leptin
expression and secretion by adipocytes (via both prejunctional
and postjunctional mechanisms) and increasing leptin clearance
by the kidney. This accounts for the unexpected reduction by
JD5037 of food intake in fed animals, but not for its delay of
meal initiation in fasted animals (Tam et al., 2012), which are
expected to have low levels of leptin.
Although the picture seems to be quite clear in vitro, data
obtained in vivo mostly with CB1 agonists or inverse agonists
have provided contrasting results as to the actual contribution
of adipocyte CB1 receptors to the control of energy metabolism.
Thus, controversy exists as to whether these receptors control
WAT lipogenesis and/or lipolysis only at the prejunctional (Mølhøj
et al., 2010) or also at the postjunctional (Jourdan et al., 2010)
level. Initial results with conditional and adipocyte-specific
CB1/ mice (Mancini et al., 2010) indicate that CB1 receptors
in these cells do mediate at least part of the WAT accumulation
and insulin resistance due to a prolonged HFD. Furthermore,
recent evidence obtained in baboons through the use of radiola-
beled FAs and TGs confirms the importance of the WAT in
weight-loss-independent lipogenic and insulin-sensitizing
actions of rimonabant (Vaidyanathan et al., 2012).
Functional CB1 receptors have been found also in brown
adipocytes (Perwitz et al., 2006; Starowicz et al., 2008).
However, most of the available data, obtained through the
use of pharmacological and genetic tools inactivating CB1
receptors, point to inhibition of sympathetic inputs onto the
brown adipose tissue (BAT) and decreased thermogenesis as
one of the most important mechanisms through which CB1
receptor activation reduces energy expenditure by BAT and
causes WAT accumulation in DIO mice (Bajzer et al., 2011;Quarta et al., 2010). The relevance of this to human obesity is
yet unexplored.
Plasma Endocannabinoid Levels as Biomarkers of WAT
Distribution and Insulin Resistance in Obesity
Whatever the role of white adipocyte CB1 receptors, WAT AEA
and 2-AG levels are usually deregulated in animal and human
obesity. In particular, (1) in the visceral (i.e., intra-abdominal)
WAT, the levels of both endocannabinoids and 2-AG are higher
in DIO mice and in obese human subjects, respectively (D’Eon
et al., 2008; Matias et al., 2006); (2) in the subcutaneous WAT,
2-AG and/or AEA levels are reduced in obese rodents (Izzo
et al., 2009; Starowicz et al., 2008) and 2-AG levels are reduced
in obese/T2D subjects and increased by weight loss (Annuzzi
et al., 2010; Bennetzen et al., 2011); and (3) the amount of
visceral, but not subcutaneous, WAT of obese human subjects
is directly correlated with the plasma levels of 2-AG (Blu¨her
et al., 2006; Coˆte´ et al., 2007). Thus, it is tempting to speculate
that, when present, high circulating 2-AG levels in obese
subjects reflect, in part, the upregulation of this endocannabi-
noid in visceral, but not subcutaneous, WAT. Accordingly,
long-term weight loss and waist circumference reduction in
intra-abdominally obese men was accompanied by a strong
decrease in the plasma concentrations of 2-AG, directly corre-
lated with decreased visceral adiposity, plasma TG levels, and
insulin resistance (DiMarzo et al., 2009a). Given the very different
metabolic roles of the two major types of WAT depots and the
aforementioned prolipogenic action of CB1, deregulation of
peripheral 2-AG levels might not only be the consequence but
also one of the causes of increased visceral, at the expense of
subcutaneous, WAT, and hence of insulin resistance. On the
other hand, the circulating levels of AEA might reflect its con-
centrations in the subcutaneous WAT, particularly under condi-
tions of strongly impaired insulin signaling, since overweight/
obese type 2 diabetes (T2D) patients exhibit increased plasma
AEA and 2-AG levels (Matias et al., 2006) but increased concen-
trations of only AEA in the subcutaneous WAT (Annuzzi et al.,
2010). These data suggest that alterations of endocannabinoid
levels in human obesity might occur in both a gender- and
WAT-depot-specific and an insulin-dependent manner. Indeed,
a recent study showed higher plasma 2-AG concentrations in
men and AEA levels being correlated with adiposity and meta-
bolic parameters in women (Fanelli et al., 2012). Genetic factors
also play a role since the 385 C/A (P129T) mutation that causes
FAAH to be less stable to degradation is associated with a high
body mass index (BMI) and increased AEA levels, even when
the latter were corrected for BMI (Sipe et al., 2010), and with a
better initial percentage of excess weight loss 9 and 12 months
after biliopancreatic diversion (de Luis et al., 2010).
Theoretically, stimulation of FAAH expression by insulin,
observed in the subcutaneous tissue of lean but not obese
patients (Murdolo et al., 2007), should control AEA, but not 2-
AG, levels. It might thus explain not only the finding of decreased
AEA but not 2-AG plasma levels in normoglycemic, and much
less so in T2D, subjects after hyperinsulinemic/euglycemic
clamps (Di Marzo et al., 2009c) and the postprandial decrease
in AEA but not 2-AG plasma levels in normoweight but not
obese subjects (Gatta-Cherifi et al., 2012; Matias et al., 2006),
but also the observation of increased AEA but not 2-AG levels
in the subcutaneous WAT of obese T2D subjects (AnnuzziCell Metabolism 17, April 2, 2013 ª2013 Elsevier Inc. 479
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women are negatively correlated with FAAH messenger RNA
(mRNA) expression in subcutaneous WAT (Engeli et al., 2005).
Interestingly, it was recently shown that FAAH, but not MAGL,
activity is increased in isolated adipocytes from non-insulin-
resistant obese individuals in a way directly correlated with
BMI (Cable et al., 2011), thus confirming the important role of
insulin sensitivity, rather than BMI, in controlling WAT and
circulating AEA levels via the upregulation of this enzyme. How-
ever, FAAH deregulation might also affect 2-AG levels, since
increased plasma 2-AG levels correlate with decreased FAAH
mRNA in visceral WAT of obese patients (Blu¨her et al., 2006).
In summary, although this possibility needs to be confirmed
by studies employing cohorts of patients larger than those
analyzed thus far, and via standardized methods dealing with
the variability of and establishing reference levels for plasma
endocannabinoids, the latter might in the future be considered
as biomarkers of intra-abdominal versus subcutaneous WAT
accumulation, in the case of 2-AG, and insulin-resistance in
subcutaneous WAT, in the case of AEA. Prospective studies in
which longitudinal analyses of multiple parameters of intra-
abdominal obesity and their response to treatment are still
required to assess whether plasma 2-AG levels might be used
as predictive of responsiveness to therapeutic agents that
counteract CB1 activity or as efficacy indicators of lifestyle or
other pharmacological interventions aimed at specifically
reducing this typical sign of the metabolic syndrome.
Hepatocyte Endocannabinoids: Glucose and Lipid
Metabolism and Hepatic Insulin Resistance
The liver plays key roles in regulating total body energy homeo-
stasis, and its ability to do so is greatly affected by the
occurrence of pathological conditions such as alcoholic or
nonalcoholic fatty liver disease (NAFLD), which contribute to
hepatic insulin resistance and end-stage liver disease-related
mortality (Parekh and Anania, 2007). TG accumulation in hepato-
cytes results from the incorporation of plasma free fatty acids
and de novo fat synthesis (Postic and Girard, 2008b). It is now
well accepted that the hepatocytes express CB1 receptors
and produce endocannabinoids (Kunos and Tam, 2011). During
conditions that induce hepatosteatosis, be it diets rich in fat or
alcohol, the liver expression of CB1 and the levels of 2-AG
and/or AEA are increased significantly in rodents (Jeong et al.,
2008; Jourdan et al., 2010; Osei-Hyiaman et al., 2005), whereas
hepatic CB1 is upregulated in patients with hepatosteatosis
(Liu et al., 2012; Mendez-Sanchez et al., 2007). This increased
ECS tone is due in part to the activation of a feed-forward
loop, as CB1 upregulation by both high fat and alcohol is CB1
dependent (Jourdan et al., 2010; Mukhopadhyay et al., 2010)
and AEA increases CB1 expression in organotypic liver slices,
whereas rimonabant decreases it (Jourdan et al., 2012).
Additionally, hepatic CB2 mRNA is induced in obese mice, and
CB2 agonism increases HFD-induced hepatosteatosis (Deveaux
et al., 2009). CB1 and CB2 agonists increase the degree of
steatosis of oleic acid-treated immortalized human hepatocytes,
and CB2 agonism increases CB1 receptor expression (De Got-
tardi et al., 2010). Thus, CB2 receptors might also participate
in the deregulation of hepatic function.
The hepatic ECSmight contribute to fatty liver through disrup-
tion of hepatic lipogenic and lipolytic pathways and insulin480 Cell Metabolism 17, April 2, 2013 ª2013 Elsevier Inc.signaling (Gary-Bobo et al., 2007; Jeong et al., 2008; Jourdan
et al., 2010; Osei-Hyiaman et al., 2005; Osei-Hyiaman et al.,
2008) (Figure 3A). The key lipogenic transcription factor sterol
regulatory element binding transcription factor 1 (SREBF1) is up-
regulated by CB1, resulting in the enhanced expression of
acetyl-Coenzyme A (CoA) carboxylase-a (Acaca, aka Acc1)
and Fas, key enzymes in the regulation of lipogenesis. CB1
blockade causes downregulation of these enzymes (Jeong
et al., 2008; Osei-Hyiaman et al., 2005; Tam et al., 2010).
Conversely, AEA stimulates lipogenic genes in liver slices, in
a manner reversed by rimonabant (Jourdan et al., 2012). In
mice, acute pharmacological upregulation of 2-AG levels via
a single dose of an inhibitor of 2-AG hydrolysis results in a signif-
icant increase in hepatic triglyceride levels, as well as insulin
resistance, and a microarray cluster analysis identified the
functional category of lipid, fatty acid, and steroid metabolism
genes, including many SREBF1 targets, as being regulated in
a CB1-dependent manner (Ruby et al., 2011).
AMPK is a key metabolic regulator, and in the liver it controls
the expression and activity of several lipogenic factors, including
SREBF1 (Viollet et al., 2009). CB1 activation by D9-THC in rats,
and ACEA in mice on a HFD, decreases liver AMPK activity
(Kola et al., 2005; Tedescoet al., 2010),whereasCB1antagonism
increases it in organotypic liver slices (Jourdan et al., 2012). CB1
blockade by rimonabant decreases lipogenesis through AMPK
via the cAMP-dependent protein kinase A (PKA)-liver kinase B1
(LKB1) axis and downstream of Gai/o inhibition. AMPK in turn
inactivates the liver X receptor a (LXRa), which is responsible
for Srebf1 expression (Wu et al., 2011). Presumably, activation
of CB1 and Gai/o works through the same pathway but with the
opposite effects. AMPKalso increasesmitochondrialb-oxidation
of fatty acids as a result of reduced malonyl CoA levels, leading
to carnitine palmitoyltransferase 1a (Cpt1a) activation and fatty
acid shuttling into mitochondria (Viollet et al., 2009). Accordingly,
rimonabant decreasesmalonyl CoA in the liver of mice on a high-
sugar and high-fat diet (Jourdan et al., 2010) and increases liver
mitochondrial oxygen consumption and lipid b-oxidation in
mice and liver slices (Flamment et al., 2009; Jourdan et al.,
2012), whereas CB1 agonism decreases Cpt1a activity to
increase liver lipogenesis (Osei-Hyiaman et al., 2008). Addition-
ally, global or liver-specific CB1 knockout results in increased
hepatic AMPK activation and Cpt1a levels and activity (Jeong
et al., 2008; Osei-Hyiaman et al., 2008). CB1-mediated AMPK
inhibition not only inhibits mitochondrial activity but also leads
to decreased mitochondrial biogenesis in the liver of mice on
a HFD (Tedesco et al., 2010). The ECS might impinge upon
AMPK also indirectly via inhibition of adiponectin production
(Kim et al., 2012a), since adiponectin stimulates hepatic AMPK
activation and fatty acid entry intomitochondrial b-oxidation (Ya-
mauchi et al., 2002) (Figure 3A).
Fatty liver caused by HFD is also associated with insulin resis-
tance, characterized by the elevation of hepatic glucose produc-
tion, plasma hyperglycemia, and hyperinsulinemia (Parekh and
Anania, 2007; Postic and Girard, 2008a). Given the effects of
the ECS on hepatosteatosis, it is therefore not surprising that
CB1 activation in humans and rats is associated with decreased
glucose tolerance (Bermu´dez-Siva et al., 2006). Therefore, the
amelioration of liver steatosis observed with CB1 antagonism
or knockout is similarly associated with an improvement in
Figure 3. Endocannabinoid Role in Lipid
and Glucose Metabolism in the Liver
Endocannabinoid control of hepatocyte (A)
triglyceride levels and (B) insulin sensitivity and
glucose production. In (B), note how hepatocyte
CB1 activation has been proposed to inhibit insulin
signaling by two mechanisms, i.e., upregulation
of inhibitory phosphorylation of insulin receptor
substrate (IRS) and stimulation of inhibitory
dephosphorylation of insulin-activated protein
kinase b (AKT2) via the upregulation of the S/T
phosphatase PH domain and leucine-rich repeat
protein phosphatase 1 (PHLPP11) downstream of
a pathway dependent on heat shock protein 5
(HSPA5), PRKR-like endoplasmic reticulum kinase
(PERK) and eukaryotic translation initiation factor
2 subunit 1 alpha (eIF2a) and subsequent endo-
plasmic reticulum (ER) stress (Liu et al., 2012).
CB1-activated ER stress is also implicated in the
upregulation of the liver-specific transcription
factor cAMP-responsive element-binding protein
H (CREBH), which increases gluconeogenic gene
expression and glucose production via Lipin1
and potential feed-forward onto endocannabinoid
(EC) biosynthesis (Chanda et al., 2011). ACACA,
acetyl-Coenzyme A carboxylase-a; CPT1a,
carnitine palmitoyltransferase 1a; CREBH, cAMP-
responsive element-binding protein H; DAG,
diacyl glycerol; FA, fatty acid; FAS, fatty acid
synthase; HFD, high-fat diet; HSC, hepatic stellate
cell; IDE, insulin-degrading enzyme; IR, insulin
receptor; LKB1, liver kinase B1; LXRa, liver X
receptor a; PKA, cAMP-dependent protein kinase
A; PKCε, protein kinase Cε; RAR, retinoic acid
receptor; SREBF1, sterol regulatory element
binding factor 1.
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2012; Osei-Hyiaman et al., 2008; Ravinet Trillou et al., 2004).
Mice with hepatocyte-specific knockout of CB1 are not pro-
tected from increased weight and total adiposity in response to
DIO but are resistant to the development of hepatosteatosis
and insulin insensitivity (Liu et al., 2012; Osei-Hyiaman et al.,
2008). However, acute upregulation of 2-AG levels results in
decreased glucose tolerance after only a few hours (Ruby
et al., 2011), and more-recent studies have highlighted direct
(i.e., fatty-liver-independent) effects of hepatic CB1 receptors
on insulin sensitivity in obesity. Mice in which CB1 expression
was reintroduced on a CB1 global knockout at levels similar to
those induced by DIO (denoted as htgCB1/ [hepatocyte
transgenic CB1/] mice) provided important insights into the
molecular mechanism involved in this latter phenomenon (Liu
et al., 2012). The htgCB1/ mice exhibit much higher basal
circulating glucose and insulin levels, and while they remain
lean when maintained on a HFD, exactly like CB1/ mice,
they develop strong hepatic and systemic insulin resistance,Cell Metabolismopposite to mice with hepatocyte-
specific CB1 knockout, which become
obese but remain insulin-sensitive, sup-
porting the notion that hepatic CB1
reduces insulin sensitivity without affect-
ing body weight (Liu et al., 2012; Osei-
Hyiaman et al., 2008). Increased insulin
levels in htgCB1/ mice are associated
with lower insulin-degrading enzyme(IDE) expression in the liver, which is also observed in wild-
type mice with DIO, showing that hepatic CB1 is involved in
regulating insulin clearance. Further, the study indicated that
hepatic CB1 inhibits insulin signaling by upregulation of inhi-
bitory phosphorylation of insulin receptor substrate (IRS) and
stimulation of inhibitory dephosphorylation of insulin-activated
protein kinase b (PKBb/AKT2) via an endoplasmic reticulum
(ER) stress-dependent pathway (Liu et al., 2012) (Figure 3B).
The htgCB1/ mice also exhibited increased glycogen phos-
phorylase-a activity, indicating that the increased hepatic
glucose production observed was due to an increase in glyco-
genolysis. Interestingly, ER stress seems to also be implicated
in the upregulation of gluconeogenic gene expression and
glucose production by 2-AG in primary human hepatocytes,
which occurs via CB1-mediated upregulation of the ER stress
liver-specific transcription factor cAMP-responsive element
binding protein 3-like 3 (Crebh) (Chanda et al., 2011). Thus,
CB1 causes hepatocyte ER stress during obesity, perhaps also
through AMPK (Dong et al., 2010), and this effect is critical to17, April 2, 2013 ª2013 Elsevier Inc. 481
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2-AG also induces, via CREBH activation, the expression of
Lipin1, a phosphatidic acid phosphatase, and the subsequent
release of DAG and phosphorylation of protein kinase C-ε, with
inhibition of hepatic insulin receptor signaling. Knockdown of
CREBH or CB1 antagonism attenuates 2-AG-mediated induc-
tion of Lipin1 gene expression, decreases DAG production in
mouse liver, and restores insulin receptor signaling (Chanda
et al., 2011). Given the role of DAG in the biosynthesis of 2-AG,
this mechanism might generate an ECS-mediated feed-forward
loop leading to hepatic insulin resistance (Figure 3B).
Control of Metabolism by the Peripheral
and Nonneuronal Endocannabinoid System:
Emerging Mechanisms
Muscle Endocannabinoids: Insulin Sensitivity
and Beyond
Muscle is a key tissue in the regulation of energy homeostasis,
not only during periods of high activity, requiring large amounts
of energy, but also during rest or basal activity, making it a major
site of fatty acid b-oxidation and sink for glucose and thus a prin-
cipal site of insulin-induced glucose mobilization (Abdul-Ghani
and DeFronzo, 2010). It is now well accepted that muscle cells
produce endocannabinoids and express a large number of the
components of the ECS, including its synthesizing and degrad-
ing enzymes and its receptors (Cavuoto et al., 2007a, 2007b;
Crespillo et al., 2011; Eckardt et al., 2009; Esposito et al.,
2008; Lipina et al., 2010). There exist, however, discrepancies
within the literature as to whether the muscle ECS becomes de-
regulated under conditions of obesity and/or insulin resistance.
In primary skeletal muscle myotubes of lean and obese subjects,
CB1 gene expression remains unchanged (Cavuoto et al.,
2007a). In rats fed a HFD, abdominal wall skeletal muscle gene
expression of CB2 and Magl is decreased and increased,
respectively (Crespillo et al., 2011). In genetically obese Zucker
rats, CB1 mRNA levels in soleus are decreased (Lindborg
et al., 2010), whereas AEA levels are increased (V.D., unpub-
lished data). However, CB1 expression in soleus muscle from
mice on a HFD is increased (Pagotto et al., 2006). These data
make it difficult to predict the possible effects of obesity on over-
all endocannabinoid tone in muscle and indicate that ECS
response to the metabolic state of the organism might have
muscle-subtype- or genetic-specific differences. In the soleus
muscle from mice on a HFD for 14 weeks, 2-AG, but not AEA,
levels were significantly elevated at the beginning of the study
and near the end, when the animals had obesity and hypergly-
caemia, but not in the middle (Matias et al., 2008b). This sug-
gests that muscle endocannabinoid production is modulated
by HFD and that compensatory mechanisms might overcome
these changes initially but not once the organism has become
obese and insulin resistant.
Pharmacological inhibition of CB1 activity in obese humans
or in genetically or diet-induced obese rodents results in
increased energy expenditure/oxygen consumption, which
was not explainable by increased physical activity but rather
associated with elevated FA oxidation (Addy et al., 2008; Herling
et al., 2008; Kunz et al., 2008; Liu et al., 2005). Accordingly,
studies on isolated myotubes indicate that the ECS has a nega-
tive impact on muscle oxidative pathways. AMPKa1 is a positive482 Cell Metabolism 17, April 2, 2013 ª2013 Elsevier Inc.modulator of glucose and fatty acid oxidation and mitochondrial
biogenesis, and while in myotubes from lean and obese donors
AEA only produces a small increase in its levels, CB1 inhibition
by AM251 significantly increases AMPKa1 (similar to results
obtained in liver) (Cavuoto et al., 2007a; Jourdan et al., 2012).
In ‘‘lean’’ myotubes, however, AEA does increase the expression
of pyruvate dehydrogenase kinase isoenzyme 4 (PDK4), an
inhibitor of the pyruvate dehydrogenase complex that links
glycolysis to the citric acid cycle and thus a negative regulator
of mitochondrial glucose oxidative metabolism that is downre-
gulated by insulin (Majer et al., 1998), whereas CB1 antagonism
decreased the expression of this enzyme (Cavuoto et al., 2007a).
These data, taken together with CB1 reduction of muscle mito-
chondrial biogenesis (Tedesco et al., 2010), imply that overac-
tivity of the ECS in this tissue might drive defective skeletal
muscle oxidative metabolism through impaired mitochondrial
oxidative phosphorylation (Abdul-Ghani and DeFronzo, 2010).
Chronic treatment of ob/ob mice and lean or obese Zucker
rats with rimonabant resulted in increased glucose uptake in
the soleus muscle (Lindborg et al., 2011; Liu et al., 2005).
Conversely, systemic (intravenous), but not central (intracere-
broventricular), administration of a single dose of the CB1/CB2
agonist, HU210, resulted in the CB1-dependent reduction of
whole-body glucose clearance and glucose transport into
muscle but not adipose tissue (Song et al., 2011), indicating
that HU210 may act directly on muscle CB1 receptors. Indeed,
in soleus muscle, explant cultures from lean and insulin-resistant
obese Zucker rats, AEA and rimonabant significantly decreased
and increased both basal and insulin-dependent glucose import,
respectively (Lindborg et al., 2010). In this study, as in subse-
quent work (Lindborg et al., 2011), no effects were observed
on canonical insulin-independent or -dependent glucose trans-
port pathways. Yet other studies have reported that, instead,
CB1 impinges on muscle insulin signaling. In vivo, acute
treatment of mice with HU210 resulted in decreased insulin-
dependent AKT phosphorylation in hind leg muscle (Song
et al., 2011). These results are consistent with in vitro data in
L6 rat myotubes in which rimonabant or CB1 knockdown
increased glucose uptake, with the former being accompanied
by increased expression of phosphatidylinositol 3-kinase
(PI3K) catalytic and regulatory subunits and subsequently by
AKT and mitochondrial pyruvate dehydrogenase lipoamide
kinase isozyme 1 (PDK1) and protein kinase cz (PKCz) activation
(Esposito et al., 2008). Further, in an in vitro study that points to
an endogenous role for ECS-mediated regulation of insulin
sensitivity in mice, it was found that adipocyte-conditioned
media (24 hr treatment) or AEA (24 or 1 hr treatment) inhibited
insulin-dependent glucose uptake and AKT activation in skeletal
muscle cells in a CB1-dependent manner (Eckardt et al., 2009).
Conversely, in another study still in L6 myotubes, while 24 hr
treatment with ACEA had no effect on insulin-dependent AKT
activation, rimonabant sensitized AKT to insulin-dependent
activation and increased phosphorylation of its targets, forkhead
box O3A (Foxo3a) and glycogen synthase kinase 3 a/b (GSK3a/
b) (Lipina et al., 2010). Despite some inconsistencies, altogether
these data indicate that the ECS negatively regulates the
P13K-AKT and P13K-PDK-PKCz pathways downstream of
insulin, which are required for glucose transporter 1/4 (GLUT1/
4) translocation and glucose uptake. However, and surprisingly,
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be altered, indicating that the ECS may posttranslationally regu-
late these proteins.
It should be noted that, in addition to the above actions, the
ECS modifies other insulin signaling effectors as well. For
instance, high AEA levels caused inhibitory insulin receptor
substrate 1 (IRS1) phosphorylation (Eckardt et al., 2009). Further,
the ECS modulates the MAPK arm of the insulin pathway that
regulates gene expression and cell proliferation, as rimonabant
stimulated, and the CB1 agonist ACEA inhibited, insulin-depen-
dent extracellular signal-regulated kinase 1/2 (ERK1/2) activa-
tion (Lipina et al., 2010). Finally, at high concentrations, AEA
activated p38 (in a sustained manner) and ERK1/2 (transiently)
in primary human skeletal muscle cells (Eckardt et al., 2009),
an effect that might be due to activation of non-CB1 receptors
and underlie some of the beneficial effects of intensive exercise,
given the stimulatory effect of the latter on plasma AEA levels
(for a review, see Heyman et al., 2012).
Pancreatic Endocannabinoids: Direct Effects on Insulin
Secretion or b Cell Health?
The understanding of the role of the endocannabinoid system
in b cells has been hindered by controversy regarding the pres-
ence of CB1 and CB2 receptors in these cells. However, most
researchers agree that b cells do express the former receptor,
although it is not clear yet whether CB1 activation controls only
insulin signaling (and hence b cell health), as in hepatocytes
and myotubes, or also insulin release. Furthermore, as in the
case of adipocytes, the contribution of b cell CB1 receptors to
the control of energy homeostasis has found so far support
only from in vitro studies. Current data suggest that, although
counterintuitive given the reduction of glucose tolerance
observed after acute or chronic systemic administration of
CB1 agonists (Bermu´dez-Siva et al., 2006; Liu et al., 2012),
in vitro stimulation of these receptors in b cells enhances, rather
than reduces, either basal or glucose-stimulated (or both) insulin
release (Bermu´dez-Silva et al., 2008; Li et al., 2010; Matias et al.,
2006). Accordingly, when using pancreatic Langerhan’s islet
preparations from lean and Zucker diabetic fatty rats, the latter
of which likely exhibit elevated endocannabinoid levels (Izzo
et al., 2009) much in the same way those from DIO mice do
(Starowicz et al., 2008), Getty-Kaushik and colleagues (2009)
found that CB1 blockade with rimonabant decreases basal
insulin hypersecretion (Getty-Kaushik et al., 2009). Rimonabant
also decreased nonstimulated insulin hypersecretion in islets
from lean rats that had been treated with high glucose for
24 hr, a condition similar to that found to enhance basal endo-
cannabinoid levels in a rat b cell line (Matias et al., 2006). On
the other hand, rimonabant did not affect glucose-stimulated
insulin secretion by islets from obese rats or glucose-treated
islets from lean rats, whereas it did in untreated islets from lean
rats. Thus, CB1 antagonism in islets reduces insulin secretion
only when this is elevated above normal levels by diet or obesity,
possibly because of higher endocannabinoid tone during these
conditions. Especially if it also contributes to insulin resistance
in the liver or skeletal muscle (see above), endocannabinoid
overactivation of CB1 receptors in b cells during obesity, and
the subsequent hypersecretion of insulin, might first represent
an attempt at compensation for insulin resistance and, later, in
the continued presence of insulin signaling impairment,contribute to b cell stress and damage. This might explain why
another CB1 receptor inverse agonist, ibipinabant, attenuated
b cell loss in Zucker diabetic fatty rats independently of its effects
on body weight (Rohrbach et al., 2012).
Recently, another mechanism has been put forward that
might explain why CB1 receptor blockade ameliorates b cell
damage in obesity. It was shown that CB1 activation inhibits
insulin signaling in b cells by preventing insulin-stimulated insulin
receptor (IR) autophosphorylation in a Gai-dependent manner,
whereas pharmacologic blockade of CB1 results in enhanced
IR signaling through the AKT2 pathway in b cells and leads to
increased b cell proliferation and mass both in vitro and in vivo
in diabetic db/db mice (Kim et al., 2011). From the molecular
point of view, the mechanism by which CB1 inhibits IR signaling
seems to be quite novel. In fact, the same authors reported in
a subsequent study (Kim et al., 2012b) that CB1 forms a hetero-
meric complex with the IR and Gai, leading to inhibition of the
kinase activity of the IR by directly binding to the activation
loop in the tyrosine kinase domain of this protein. IR impairment
then leads to reduced phosphorylation of the proapoptotic
protein Bad and subsequent stimulation of its apoptotic activity,
thereby causing b cell death. Therefore, pharmacological
blockade of CB1 receptors might represent a therapeutic oppor-
tunity for diabetes, independent of its other actions on body
weight, WAT inflammation, and hepatic and muscle insulin
resistance.
Endocannabinoid Congeners and Metabolites and Their
Emerging Role in Metabolic Control
As mentioned above, both AEA and 2-AG are biosynthesized
in tissues together with congeners, the N-acyl-ethanolamines,
and MAGs, which may stimulate metabolically active non-CB1,
non-CB2 receptors, and are inactivated by FAAH and MAGL,
respectively. PEA and, particularly, OEA activation of PPARa,
unlike CB1, may lead to food-intake inhibition, lipolysis in the
liver and adipose tissue, and induction of satiety via small intes-
tine-mediated mechanisms (Schwartz et al., 2008). Also, activa-
tion of TRPV1, a potential target for OEA, PEA, and AEA (Di
Marzo and De Petrocellis, 2010), stimulates lipolysis and
improves mitochondrial activity in the skeletal muscle (Luo
et al., 2012), two effects that are again the opposite of those ex-
erted by CB1 activation (Tedesco et al., 2010). On the other
hand, MAGs such as 2-oleoyl- and 2-linoleoyl-glycerol activate
GPR119 in the small intestine, with subsequent stimulation of
GLP-1 release and inhibitory and stimulatory effects of food
intake and insulin secretion, respectively (Lan et al., 2012; Han-
sen et al., 2012). Although the role of endocannabinoid conge-
ners in energy homeostasis and its pathological perturbations
has not yet been fully investigated, stimuli leading to endocanna-
binoid biosynthesis and inactivation may also cause alterations
in the tissue levels of these other mediators, the action of which
might reinforce or, more likely, oppose that of CB1 receptor
activation. Furthermore, given the important impact of the
diet on the FA composition of phospholipid classes acting as
ultimate biosynthetic precursors for endocannabinoids and
their congeners, it’s intriguing to speculate that the role of this
‘‘endocannabinoidome’’ in energy homeostasis, as well as in
the etiopathology of metabolic disorders, might also depend
on dietary factors, which, however, might or might not affect inCell Metabolism 17, April 2, 2013 ª2013 Elsevier Inc. 483
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endocannabinoids, which are ultimately derived from AA and
hence linoleic acid) and negative (i.e., palmitic-, oleic-, or lino-
leic-acid-containing N-acylethanolamines and MAGs) energy
balance. In this sense, it is interesting to observe how a diet
rich in linoleic acid was recently suggested to lead to obesity in
mice in part by engendering excess peripheral endocannabinoid
levels (Alvheim et al., 2012).
The co-occurrence in tissues of lipid mediators with similar
biosynthetic and inactivating pathways but opposing metabolic
actions may complicate the correct interpretation of data ob-
tained in genetically modified mice in which such pathways
have been inactivated. An example of this situation is the recently
described phenotype of mice in whichMagl was overexpressed
in the small intestine (Chon et al., 2012), where activation of CB1
inhibits satiety. These mice are characterized by reduced energy
expenditure and propensity to obesity after a HFD, a behavior
opposite of what would be expected from a chronic reduction
of 2-AG levels and also of that observed when the enzyme is
overexpressed in forebrain neurons (Jung et al., 2012). However,
if one remembers that MAGL overexpression in the small intes-
tine may also lead to reduced activation of GPR119 in entero-
crine L-cells by MAGs other than 2-AG, and subsequently to
reduced release of GLP-1, one may well expect obesity in
these mice. Likewise, it is possible that Magl-null mice do not
exhibit the expected propensity to obesity and, in fact, show
attenuated diet-induced insulin resistance (Taschler et al.,
2011) because the action of elevated MAGs in metabolically
active peripheral tissues expressing GPR119 receptors predom-
inates on CB1 activation by upregulated 2-AG. However, as
expected, Faah-null mice on a HFD exhibit stronger WAT accu-
mulation, high plasma TG levels, and glucose intolerance as
compared to wild-type mice (Tourin˜o et al., 2010), despite the
fact that they contain higher levels not only of the orexigenic
and lipogenic mediator, AEA, but also of the anorexigenic and
lipolytic mediator, OEA. Thus, one may speculate that concom-
itant activation of PPARa and TRPV1 by OEA (and PEA) in these
mice is not sufficient to override the effect of CB1 overactivation
by AEA.
Recently, we have also investigated the potential role in WAT
biology of another proposed route of endocannabinoid catabo-
lism, i.e., that catalyzed by COX-2 and leading to prostaglandin
analogs of AEA and 2-AG (Kozak et al., 2002). We found that
the former metabolites, also known as prostamides, and in
particular prostamide F2a, are produced in preadipocytes at
the expense of AEA and exert antiadipogenic actions in these
cells by activating a non-FP (prostaglandin F receptor), non-
CB1 receptor (C.S., N. Poloso, D. Woodward, and V.D., unpub-
lished data). We proposed that preadipocyte prostamide
signaling represents a negative paracrine feedback mechanism
to switch from an adipogenic (i.e., AEA) to an antiadipogenic
pathway, which would be inhibited under conditions requiring
the presence of new adipocytes, such as after a short period
of HFD. However, during obesity, which is accompanied by
COX-2 (Hsieh et al., 2010) and AEA level upregulation, FAAH
downregulation, and inflammation in the WAT, the formation of
prostamide F2a might be enhanced, thus increasing the number
of hypertrophic adipocytes at the expense of new small adipo-
cytes and further favoring WAT inflammation.484 Cell Metabolism 17, April 2, 2013 ª2013 Elsevier Inc.New Therapies for Correction of Endocannabinoid
Dysregulation in Metabolic Disorders
To date, themajority of efforts to deal with upregulated ECS tone
under conditions of excessive adiposity and metabolic deregu-
lation have dealt with pharmacological antagonism of the CB1
receptor, exemplified by the development of the systemically
penetrant CB1 inverse agonist, antiobesity drug rimonabant.
However, the potential consequences associated with this
drug’s central side effects have resulted in the abandonment
of pursuits to produce similar compounds. The development of
neutral antagonists and peripherally restricted inverse agonists
at CB1 receptors is being actively pursued (for a review, see
Silvestri and Di Marzo, 2012) and has already provided very
promising results at the preclinical level, particularly in terms of
their reversal of insulin and leptin resistance and also of unex-
pected differences in the appetitive and metabolic profile of
one such class of compounds versus the other (Tam et al.,
2010, 2012) (Table 1). Given that at least part of the increased
pathological tone of the ECS can be attributed to increased
endocannabinoid biosynthesis, the regulation of this process
also presents a seemingly viable strategy to regulate the
ECS. Evidence of the efficacy of this strategy has been provided
by the manipulation of 2-AG levels in two different ways.
Systemic administration of DAGL inhibitors decreased 2-AG
biosynthesis and inhibited palatable or HFD intake (Bisogno
et al., 2009; Bisogno et al., 2012), whereas the overexpression
of Magl specifically within forebrain neurons in mice resulted
in increased energy expenditure and decreased weight gain on
a HFD (Jung et al., 2012).
It is now accepted that dietary intake of the n-3 polyunsatu-
rated fatty acids (PUFAs) eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) reduce the levels of AA-esterified
phospholipids (Kinsella, 1990), which include the sn-2- and
sn-1-AA-containing phospholipids acting as ultimate precursors
for 2-AG and AEA, respectively (Di Marzo, 2008b). Treatment
of mouse adipocytes with AA increases 2-AG levels, whereas
DHA or EHA decrease AEA and 2-AG levels with concomitant
reduction of AA-esterified phospholipids (Matias et al., 2008a).
Thus, dietary n-3 PUFAs may be able to correct an overactive
ECS bymodulating endocannabinoid precursor levels (Di Marzo,
2008b; Kinsella, 1990; Piscitelli et al., 2011). In fact, a linoleic-
acid-enriched diet elevated peripheral AEA and 2-AG levels
along with inducing obesity, unless high levels of DHA and
EPA were included in the diet (Alvheim et al., 2012). Several
in vivo studies with dietary n-3-PUFA-rich fish or krill oils have
shown that such treatments reduce peripheral endocannabinoid
levels without weight loss in rodents and humans, and in rats
this effect occurs concomitantly to reduced ectopic fat in the
liver and heart (Banni et al., 2011; Batetta et al., 2009; Di Marzo
et al., 2010; Piscitelli et al., 2011). More recently, it was shown
that dietary phospholipids enriched in EPA and DHA are superior
to the corresponding TGs at ameliorating the metabolic profiles
of obese mice, including significant reductions in hepatosteato-
sis, circulating insulin levels, and WAT hypertrophy (Rossmeisl
et al., 2012). However, although generally less effective at
modulating brain endocannabinoid tone in adult mice, changes
in dietary n-3 PUFA must be considered with caution in
newborns as it can cause deep and long-lasting alterations in
brain phospholipid composition and function (Lafourcade
Table 1. Therapeutic Strategies against Obesity and the Metabolic Syndrome that Are Based on or Affect Endocannabinoid Deregulation
Therapy
Inhibitory Effect
on EC Tone
Reduction of
Food Intake
Reduction of
Body Weight
Reduction of
Glucose
Intolerance and
Insulin Resistancea
Reduction of
Plasma
Triglycerides
Reduction of
Visceral
Adipose
Tissueb
Reduction of
Liver Fat
Central Side
Effects References
CB1 inverse
agonists
In all tissues where EC
levels are higher and/or
CB1 is constitutively
coupled to G protein
Yes, transient Yes Yes Yes Yes Yes Yes (Addy et al., 2008;
Bajzer et al., 2011;
Colombo et al., 1998;
Gary-Bobo et al., 2007;
Jourdan et al., 2010;
Kim et al., 2012a;
Mølhøj et al., 2010;
Rohrbach et al., 2012,
Vaidyanathan et al., 2012)
CB1 neutral
antagonists
In all tissues where
EC levels are higher
Yes Yes Yes Yes Not yet assessed Not yet
assessed
Not yet fully
assessed
(Silvestri and Di Marzo,
2012)
Peripherally
restricted CB1
blockers
In all peripheral
tissues where EC
levels are higher
and/or CB1 is
constitutively
coupled to G protein
Yes, through
resensitization to
leptin, observed
with a CB1
inverse agonists
Yes Yes Yes Not yet assessed Yes No (Silvestri and Di
Marzo, 2012;
Tam et al., 2010, 2012)
DAGL
inhibitors
In all tissues where
EC levels are higher
Yes Yes Not yet
assessed
Not yet
assessed
Not yet assessed Not yet
assessed
Not yet
assessed
(Bisogno et al., 2009,
2012)
Dietary n-3
PUFAs
In all peripheral
tissues where EC
levels are higher
No No Yes Yes Not yet assessed Yes No (Banni et al., 2011;
Batetta et al., 2009;
Di Marzo et al., 2010;
Matias et al., 2008a,
Piscitelli et al., 2011;
Rossmeisl et al., 2012)
Lifestyle
(exercise +
caloric
restriction)
Plasma EC
levels
– Yes Yes Yes Yes Yes No (Bennetzen et al., 2011;
Di Marzo, et al., 2009a;
Heyman et al., 2012)
EC, endocannabinoid; n-3 PUFAs, n-3 polyunsaturated fatty acids (i.e., docosahexaenoic and eicosapentaenoic acids).
aFasting glucose or insulin, oral glucose tolerance test.
bAs assessed by waist circumference or computer tomography scans in humans.
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Reviewet al., 2011; D’Asti et al., 2010). Furthermore, since dietary EPA
and DHA may reduce not only endocannabinoid levels but also
those of other AA-derived metabolites, while increasing the
tissue concentrations of n-3-PUFA-containing ethanolamides
and glycerol esters potentially acting at noncannabinoid recep-
tors (Brown et al., 2013), one will need to evaluate also the
distinct role of each of these metabolites in n-3-PUFA-induced
metabolic benefits. At any rate, the use of EPA andDHA as nega-
tive regulators of peripheral endocannabinoid upregulation
merits further study and the development of specific clinical trials
as it may provide a more easily applied regime for the prevention
and treatment of the metabolic syndrome.
Concluding Remarks: The Dawn of a New Beginning?
Research in the last decade has considerably increased our
knowledge of the complexities and peculiarities of the ECS
and what is emerging as its crucial intermediary role between
circulating hormones and locally acting neurotransmitters or
neuropeptides in nearly all aspects of energy homeostasis
control. We are now starting to gather that this function is not
just played by the usual suspects, i.e., AEA and 2-AG, or CB1
receptors. Indeed, CB2 receptors, which were initially consid-
ered to be devoid of a metabolic role, are now emerging as
potential players not only, as it could be expected from their
high expression in immune cells, in the inflammatory aspects
of obesity and T2D (Pacher and Mechoulam, 2011), but perhaps
also in the physiological control of hepatic lipogenesis and
glucose tolerance at both peripheral (Agudo et al., 2010;
De Gottardi et al., 2010; Deveaux et al., 2009) and, possibly,
central (Romero-Zerbo et al., 2012) levels. However, as
compared to the great wealth of descriptive and mechanistic
information available on the function and dysfunction of CB1 in
metabolism, much work is still required to fully understand the
exact role of CB2, or of PPARs and TRPV1, in endocannabinoid
control of metabolism, or to conclude that the several endo-
cannabinoid-related mediators identified to date, through their
putative or established molecular targets, do contribute to this
already variegated scenario. Also thanks to the precocious
(and, for now, discontinued) clinical development of inverse
agonists as drugs against obesity first and T2D later, we do
know, however, that rodent data on the role of CB1 in metabolic
control can be translated to humans. Furthermore, the deregu-
lated peripheral ECS, of which plasma endocannabinoid levels
are probably a reflection, might be not only a secondary
biomarker but also a key causative factor of metabolic disorders.
Despite the fact that the strong connections between brain and
periphery in the control of body weight cannot always be teased
out experimentally with tissue-specific CB1 knockout mice,
there is sufficient evidence to suggest that the metabolic effects
of drugs counteracting CB1 activity is not only secondary to
weight loss. Clinical trials with peripherally restricted pharmaco-
logical tools or, maybe even better, yet-to-be-devised organ-
selective drugs (e.g., prodrugs exploiting the relative abundance
of certain enzymes in the liver) must confirm this hypothesis and
tell us whether it can be used to develop new and safe therapies
against dyslipidemia, insulin resistance, and b cell damage. New
endocannabinoid-based interventions are emerging, and,
despite the disappointment caused by the failure of first-gener-
ation CB1 receptor blockers, optimism still exists regarding the486 Cell Metabolism 17, April 2, 2013 ª2013 Elsevier Inc.future development of such therapies against the metabolic
syndrome.
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